Filters

Pp-137 manufacturers

Filters

None products found

pp-137

Tablets

Dossier type
CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Hypertrophic cardiomyopathy (obstructive and non-obstructive HCM) Clinical stage: Phase 2 Modality: Small molecule Mechanism / Target: Selective cardiac β-myosin heavy chain (MYH7) inhibitor — reduces hypercontractility of cardiomyocytes by decreasing actin-myosin cross-bridge formation Route / form: Oral tablet (once daily) Differentiation: Potentially wider therapeutic window for LVEF vs mavacamten; designed to avoid systolic dysfunction; next-generation profile in validated HCM target class
Manufacturer #39169

Clinical-stage muscle disease company developing precision myosin modulators. Targets skeletal and cardiac muscle diseases driven by abnormal sarcomere function. Wholly owned pipeline including Phase 3 asset for rare muscular dystrophy.
 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.